Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Two Buprenorphine Patch Formulations vs Reference
NCT03785613Phase 1Completed
- Sponsor
- Grünenthal GmbH
- Start
- Nov 2005
- Primary completion
- Mar 2006
- Modality
- Orthosteric Ligands, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of v1003 in pain (3 arms), sponsored by Grünenthal GmbH. Primary endpoints: Area under the concentration-time extrapolated to infinity at 168 hours, Area under the concentration-time curve up to the last quantifiable plasma concentration at 168 hours and 1 more. Started Nov 2005; status: completed.
02
Drugs
v1003
03
Conditions
pain
Beyond the preview
Go deeper on NCT03785613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03785613.